Literature DB >> 12571628

Airway-directed gene transfer of interleukin-10 using recombinant Sendai virus effectively prevents post-transplant fibrous airway obliteration in mice.

F Shoji1, Y Yonemitsu, S Okano, I Yoshino, K Nakagawa, Y Nakashima, M Hasegawa, K Sugimachi, K Sueishi.   

Abstract

Bronchiolitis obliterans (BO) after lung transplantation prevents a satisfactory prognosis, and recent studies suggested that interleukin-10 (IL-10) gene transfer to distant organs could inhibit BO in rodent models. Although delivery of the therapeutic gene to a local airway would be favored to minimize systemic effects, current limitations include lower gene transfer efficiency to airway epithelium. As recombinant Sendai virus (SeV) can produce dramatically efficient gene transfer to airway epithelium, we determined if SeV-mediated IL-10 gene transfer to the local airway would inhibit bronchial fibrous obliteration in murine tracheal allografts. Administration of cyclosporine A (CsA) significantly promoted not only recovery of the injured airway epithelium but also SeV-mediated IL-10 expression (CsA- versus CsA+ =228+/-78 versus 3627+/-1372 pg/graft with 5 x 10(7) pfu), thereby suggesting the requirement of epithelia for efficient gene transfer. Even at the highest expression, no significant leakage of IL-10 was evident in the systemic circulation, and the induction of interferon-gamma was completely diminished on day 7 by IL-10 gene transfer. As a result, luminal loss was significantly prevented in allografts treated with SeV-IL-10 (luminal opening, all control groups: 0% respectively, and SeV-IL-10 5 x 10(7) pfu: 25.7+/-10.5%), an effect that was enhanced by short-term CsA treatment (SeV-IL-10 5 x 10(7) pfu with CsA: 63.7+/-12.7%). We propose that SeV is a useful vector that can target airway epithelium to prevent BO avoiding putative systemic effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12571628     DOI: 10.1038/sj.gt.3301847

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

Review 1.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

2.  miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice.

Authors:  Jun Xiao; Xiao-Ming Meng; Xiao R Huang; Arthur Ck Chung; Yu-Lin Feng; David Sc Hui; Cheuk-Man Yu; Joseph Jy Sung; Hui Y Lan
Journal:  Mol Ther       Date:  2012-03-06       Impact factor: 11.454

3.  Radiation damage and radioprotectants: new concepts in the era of molecular medicine.

Authors:  M I Koukourakis
Journal:  Br J Radiol       Date:  2012-01-31       Impact factor: 3.039

Review 4.  Animal models for bronchiolitis obliterans syndrome following human lung transplantation.

Authors:  Elbert Kuo; Ankit Bharat; Sekhar Dharmarajan; Felix Fernandez; G Alec Patterson; T Mohanakumar
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  Gene Therapy: Will the Promise of Optimizing Lung Allografts Become Reality?

Authors:  Qimeng Gao; Isabel F DeLaura; Imran J Anwar; Samuel J Kesseli; Riley Kahan; Nader Abraham; Aravind Asokan; Andrew S Barbas; Matthew G Hartwig
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

6.  Gene therapy of c-myc suppressor FUSE-binding protein-interacting repressor by Sendai virus delivery prevents tracheal stenosis.

Authors:  Daisuke Mizokami; Koji Araki; Nobuaki Tanaka; Hiroshi Suzuki; Masayuki Tomifuji; Taku Yamashita; Yasuji Ueda; Hideaki Shimada; Kazuyuki Matsushita; Akihiro Shiotani
Journal:  PLoS One       Date:  2015-01-08       Impact factor: 3.240

7.  Perfluorochemical (PFC) liquid enhances recombinant adenovirus vector-mediated viral interleukin-10 (AdvIL-10) expression in rodent lung.

Authors:  John T Li; Laura A Bonneau; Jerry J Zimmerman; Daniel J Weiss
Journal:  J Inflamm (Lond)       Date:  2007-05-01       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.